头孢地尔连续肾脏替代治疗剂量推荐的前瞻性多中心药代动力学验证
该多中心前瞻性药代动力学研究纳入2022—2023年接受CRRT的ICU患者14例,effluent flow rate 2.1–5.1 L/h,稳态采血并用液相色谱-串联质谱法测定头孢地尔浓度,采用Pmetrics进行群体药代动力学分析。头孢地尔浓度最佳拟合二室模型,清除率3.5±1.5 L/h、中央室容积10.7±8.4 L。基于说明书剂量模拟,所有患者在MIC≤8 mg/L时达到100% fT>MIC,AUCdaily为1444±423 mg×h/L,与Ⅲ期临床试验观察范围一致,14例均耐受良好。结论认为现行说明书剂量推荐可实现药效学优化暴露。
要点
- 14例CRRT患者按说明书基于effluent flow rate的剂量给药,所有患者在MIC≤8 mg/L时达到100% fT>MIC。
- 模拟AUCdaily为1444±423 mg×h/L,处于Ⅲ期临床试验观察范围内,提示安全且具治疗性药物特征。
- 头孢地尔浓度最佳拟合二室模型,清除率3.5±1.5 L/h,中央室容积10.7±8.4 L。
- 头孢地尔在14例CRRT患者中耐受良好。
适用人群与场景
- 接受连续肾脏替代治疗(CRRT)的ICU患者,effluent flow rate 2.1–5.1 L/h。
- 研究期间为2022—2023年。
处置流程与药物剂量
- 按头孢地尔说明书基于effluent flow rate的剂量推荐给药。
- 药效学目标:100% fT>MIC,MIC≤8 mg/L。
研究设计与关键结果
- 研究类型:多中心前瞻性药代动力学研究;样本量14例;人群为接受CRRT的ICU患者;effluent flow rate 2.1–5.1 L/h。
- 头孢地尔浓度最佳拟合二室模型;清除率3.5±1.5 L/h,中央室容积10.7±8.4 L,k12 3.9±1.8 h⁻¹,k21 2.2±2.2 h⁻¹(均值±标准差)。
- 基于说明书剂量模拟:所有患者达到100% fT>MIC(MIC≤8 mg/L);AUCdaily均值±标准差1444±423 mg×h/L。
- 头孢地尔在14例患者中耐受良好。
证据类型、等级与局限
- 证据类型:多中心前瞻性药代动力学研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为现行说明书基于effluent flow rate的头孢地尔剂量推荐在CRRT患者中可实现药效学优化暴露。
- 作者认为头孢地尔浓度在所有患者各effluent flow rate下均超过相关MIC折点,AUCdaily处于Ⅲ期临床试验观察范围内,提示安全且具治疗性药物特征。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cefiderocol is the first antibiotic with effluent flow rate-based dosing recommendations outlined in the product label for patients receiving continuous renal replacement therapy (CRRT). We aimed to investigate the population pharmacokinetics of cefiderocol among patients receiving CRRT and validate these dosing recommendations.
METHODS: A multicenter, prospective cefiderocol pharmacokinetic study among intensive care unit patients receiving CRRT was conducted (2022-2023). Blood sampling was performed at steady-state and cefiderocol concentrations were assayed by validated liquid chromatography-tandem mass spectrometry. Population pharmacokinetic analyses were conducted in Pmetrics using R software. The free time above the minimum inhibitory concentration (f T > MIC) and total daily area under the concentration time curve (AUCdaily) were calculated.
RESULTS: Fourteen patients with effluent flow rates ranging from 2.1 to 5.1 L/h were enrolled. Cefiderocol concentrations best fitted a 2-compartment model. Mean ± standard deviation (SD) parameter estimates for clearance, central compartment volume, and intercompartment transfer constants (k12 and k21) were 3.5 ± 1.5 L/hour, 10.7 ± 8.4 L, 3.9 ± 1.8 hours-1, and 2.2 ± 2.2 hours-1, respectively. With simulations based on product label dosing recommendations, all patients achieved 100% fT > MIC up to MIC 8 mg/L with an AUCdaily (mean ± SD) of 1444 ± 423 mg × hour/L. Cefiderocol was well tolerated among the 14 patients.
CONCLUSIONS: The current package insert dosing recommendations resulted in pharmacodynamically optimized cefiderocol exposures. Cefiderocol concentrations exceeded relevant MIC breakpoints in all patients at each effluent flow rate, and AUCdaily was within the range observed in patients in the phase 3 clinical trials, suggestive of a safe and therapeutic drug profile.
参考来源
- Fouad A, Kobic E, Nicolasora NP, et al. Validation of Cefiderocol Package Insert Dosing Recommendation for Patients Receiving Continuous Renal Replacement Therapy: A Prospective Multicenter Pharmacokinetic Study. Open Forum Infect Dis. 2024. PMID: 39435320. doi:10.1093/ofid/ofae451
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。